Nantahala Capital Management LLC Has $9.27 Million Stock Holdings in Abivax SA Sponsored ADR $ABVX

Key Points

• Nantahala Capital Management LLC increased its stake in Abivax SA by 3.3%, owning 1,482,994 shares valued at approximately $9.27 million after purchasing an additional 46,947 shares.
• Several institutional investors, including Citadel Advisors LLC and Aberdeen Group plc, significantly increased their holdings in Abivax, indicating strong institutional interest in the company.
• Analysts are optimistic about Abivax's stock performance, with an average rating of "Buy" and a consensus target price of $92.33, highlighting strong projected growth potential.

Nantahala Capital Management LLC increased its position in Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report) by 3.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,482,994 shares of the company's stock after buying an additional 46,947 shares during the period. Nantahala Capital Management LLC owned 2.34% of Abivax worth $9,269,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Bank of America Corp DE lifted its position in shares of Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock worth $41,000 after buying an additional 1,990 shares during the last quarter. Cubist Systematic Strategies LLC raised its stake in shares of Abivax by 34.3% in the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company's stock valued at $63,000 after acquiring an additional 2,595 shares in the last quarter. Ameriprise Financial Inc. acquired a new stake in Abivax in the 4th quarter worth approximately $85,000. Stonepine Capital Management LLC bought a new stake in Abivax during the fourth quarter worth approximately $110,000. Finally, GAMMA Investing LLC grew its holdings in Abivax by 373.6% during the first quarter. GAMMA Investing LLC now owns 18,831 shares of the company's stock valued at $118,000 after purchasing an additional 14,855 shares during the last quarter. 47.91% of the stock is currently owned by institutional investors.

Abivax Stock Up 2.9%

Shares of ABVX traded up $2.48 during trading hours on Friday, reaching $88.03. 3,203,311 shares of the company traded hands, compared to its average volume of 959,392. The company has a quick ratio of 1.25, a current ratio of 1.25 and a debt-to-equity ratio of 1.29. The stock's fifty day moving average is $51.77 and its 200 day moving average is $22.21. Abivax SA Sponsored ADR has a 1-year low of $4.77 and a 1-year high of $92.91.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. JMP Securities boosted their price objective on shares of Abivax from $33.00 to $95.00 and gave the stock a "market outperform" rating in a research note on Wednesday, July 23rd. Citigroup restated a "market outperform" rating on shares of Abivax in a report on Friday, July 18th. Leerink Partners set a $74.00 price target on Abivax and gave the company an "outperform" rating in a research report on Wednesday, July 23rd. Piper Sandler boosted their price objective on Abivax from $70.00 to $112.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 29th. Finally, Guggenheim raised their target price on Abivax from $50.00 to $101.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $92.33.

Abivax Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.